Cargando…

Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial

Postoperative restenosis in patients with external ear canal (EEC) atresia or stenosis is a common complication following canaloplasty. Our aim in this study was to explore the feasibility of using a three dimensionally (3D)-printed, patient-individualized, drug ((dexamethasone (DEX)), and ciproflox...

Descripción completa

Detalles Bibliográficos
Autores principales: Matin-Mann, Farnaz, Gao, Ziwen, Schwieger, Jana, Ulbricht, Martin, Domsta, Vanessa, Senekowitsch, Stefan, Weitschies, Werner, Seidlitz, Anne, Doll, Katharina, Stiesch, Meike, Lenarz, Thomas, Scheper, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228097/
https://www.ncbi.nlm.nih.gov/pubmed/35745813
http://dx.doi.org/10.3390/pharmaceutics14061242
_version_ 1784734350808449024
author Matin-Mann, Farnaz
Gao, Ziwen
Schwieger, Jana
Ulbricht, Martin
Domsta, Vanessa
Senekowitsch, Stefan
Weitschies, Werner
Seidlitz, Anne
Doll, Katharina
Stiesch, Meike
Lenarz, Thomas
Scheper, Verena
author_facet Matin-Mann, Farnaz
Gao, Ziwen
Schwieger, Jana
Ulbricht, Martin
Domsta, Vanessa
Senekowitsch, Stefan
Weitschies, Werner
Seidlitz, Anne
Doll, Katharina
Stiesch, Meike
Lenarz, Thomas
Scheper, Verena
author_sort Matin-Mann, Farnaz
collection PubMed
description Postoperative restenosis in patients with external ear canal (EEC) atresia or stenosis is a common complication following canaloplasty. Our aim in this study was to explore the feasibility of using a three dimensionally (3D)-printed, patient-individualized, drug ((dexamethasone (DEX)), and ciprofloxacin (cipro))-releasing external ear canal implant (EECI) as a postoperative stent after canaloplasty. We designed and pre-clinically tested this novel implant for drug release (by high-performance liquid chromatography), biocompatibility (by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay), bio-efficacy (by the TNF-α (tumor necrosis factor-alpha)-reduction test (DEX) and inhibition zone test (for cipro)), and microbial contamination (formation of turbidity or sediments in culture medium). The EECI was implanted for the first time to one patient with a history of congenital EEC atresia and state after three canaloplasties due to EEC restenosis. The preclinical tests revealed no cytotoxic effect of the used materials; an antibacterial effect was verified against the bacteria Staphylococcus aureus and Pseudomonas aeruginosa, and the tested UV-irradiated EECI showed no microbiological contamination. Based on the test results, the combination of silicone with 1% DEX and 0.3% cipro was chosen to treat the patient. The EECI was implantable into the EEC; the postoperative follow-up visits revealed no otogenic symptoms or infections and the EECI was explanted three months postoperatively. Even at 12 months postoperatively, the EEC showed good epithelialization and patency. Here, we report the first ever clinical application of an individualized, drug-releasing, mechanically flexible implant and suggest that our novel EECI represents a safe and effective method for postoperatively stenting the reconstructed EEC.
format Online
Article
Text
id pubmed-9228097
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92280972022-06-25 Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial Matin-Mann, Farnaz Gao, Ziwen Schwieger, Jana Ulbricht, Martin Domsta, Vanessa Senekowitsch, Stefan Weitschies, Werner Seidlitz, Anne Doll, Katharina Stiesch, Meike Lenarz, Thomas Scheper, Verena Pharmaceutics Article Postoperative restenosis in patients with external ear canal (EEC) atresia or stenosis is a common complication following canaloplasty. Our aim in this study was to explore the feasibility of using a three dimensionally (3D)-printed, patient-individualized, drug ((dexamethasone (DEX)), and ciprofloxacin (cipro))-releasing external ear canal implant (EECI) as a postoperative stent after canaloplasty. We designed and pre-clinically tested this novel implant for drug release (by high-performance liquid chromatography), biocompatibility (by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay), bio-efficacy (by the TNF-α (tumor necrosis factor-alpha)-reduction test (DEX) and inhibition zone test (for cipro)), and microbial contamination (formation of turbidity or sediments in culture medium). The EECI was implanted for the first time to one patient with a history of congenital EEC atresia and state after three canaloplasties due to EEC restenosis. The preclinical tests revealed no cytotoxic effect of the used materials; an antibacterial effect was verified against the bacteria Staphylococcus aureus and Pseudomonas aeruginosa, and the tested UV-irradiated EECI showed no microbiological contamination. Based on the test results, the combination of silicone with 1% DEX and 0.3% cipro was chosen to treat the patient. The EECI was implantable into the EEC; the postoperative follow-up visits revealed no otogenic symptoms or infections and the EECI was explanted three months postoperatively. Even at 12 months postoperatively, the EEC showed good epithelialization and patency. Here, we report the first ever clinical application of an individualized, drug-releasing, mechanically flexible implant and suggest that our novel EECI represents a safe and effective method for postoperatively stenting the reconstructed EEC. MDPI 2022-06-11 /pmc/articles/PMC9228097/ /pubmed/35745813 http://dx.doi.org/10.3390/pharmaceutics14061242 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Matin-Mann, Farnaz
Gao, Ziwen
Schwieger, Jana
Ulbricht, Martin
Domsta, Vanessa
Senekowitsch, Stefan
Weitschies, Werner
Seidlitz, Anne
Doll, Katharina
Stiesch, Meike
Lenarz, Thomas
Scheper, Verena
Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial
title Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial
title_full Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial
title_fullStr Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial
title_full_unstemmed Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial
title_short Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial
title_sort individualized, additively manufactured drug-releasing external ear canal implant for prevention of postoperative restenosis: development, in vitro testing, and proof of concept in an individual curative trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228097/
https://www.ncbi.nlm.nih.gov/pubmed/35745813
http://dx.doi.org/10.3390/pharmaceutics14061242
work_keys_str_mv AT matinmannfarnaz individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT gaoziwen individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT schwiegerjana individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT ulbrichtmartin individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT domstavanessa individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT senekowitschstefan individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT weitschieswerner individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT seidlitzanne individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT dollkatharina individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT stieschmeike individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT lenarzthomas individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial
AT scheperverena individualizedadditivelymanufactureddrugreleasingexternalearcanalimplantforpreventionofpostoperativerestenosisdevelopmentinvitrotestingandproofofconceptinanindividualcurativetrial